Article thumbnail
Location of Repository

The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer

By Thierry Conroy, Céline Gavoille, Emmanuelle Samalin, Marc Ychou and Michel Ducreux

Abstract

International audienceIn 2010, the FOLFIRINOX regimen (bolus and infusional 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) emerged as a new option in patients with metastatic pancreatic cancer and a good performance status. However, at that time, some doubts were raised regarding safety issues. Similarly, no data on FOLFIRINOX were published in patients with unresectable/locally advanced or borderline resectable pancreatic cancer. This article presents the available experience with FOLFIRINOX outside clinical trials in metastatic and locally advanced pancreatic cancer patients. The safety of the regimen in patients with biliary stents and in previously treated patients is also described. FOLFIRINOX usage in clinical practice, including modification of the regimen (omission of bolus 5-fluorouracil; FOLFOXIRI regimen), is also presented. These data suggest that a phase III randomized study is warranted to further explore the role of FOLFIRINOX in locally advanced pancreatic cancer

Topics: MESH: Adenocarcinoma, MESH: Antineoplastic Combined Chemotherapy Protocols, MESH: Camptothecin, MESH: Clinical Trials as Topic, MESH: Fluorouracil, MESH: Humans, MESH: Leucovorin, MESH: Organoplatinum Compounds, MESH: Pancreatic Neoplasms, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Publisher: 'Springer Science and Business Media LLC'
Year: 2013
DOI identifier: 10.1007/s11912-012-0290-4
OAI identifier: oai:HAL:hal-01798193v1
Provided by: HAL Descartes
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://hal.univ-lorraine.fr/h... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.